Journal Club: Reversing Parkinson’s with New Neurons

Xiang-Dong Fu and Lauren Richardson

Posted October 22, 2020

Neurons do not divide or replicate, so how can we replace neurons killed by neurodegenerative diseases like Parkinson’s Disease? On the Bio Eats World Journal Club, UCSD Professor Xiang-Dong Fu and host Lauren Richardson discuss his team’s work generating new neurons in the brain by inducing non-neuronal cells to become neurons. The conversation covers how they programmed this cell type conversion, how they verified that these newly created neurons were functioning correctly, and how they demonstrated that these neurons could replace those destroyed in a mouse model of Parkinson’s Disease, reversing the disease phenotype. This work paves the way for a potential curative treatment for this and other devastating neurodegenerative and neurological diseases.

“Reversing a model of Parkinson’s disease with in situ converted nigral neurons” by Hao Qian, Xinjiang Kang, Jing Hu, Dongyang Zhang, Zhengyu Liang, Fan Meng, Xuan Zhang, Yuanchao Xue1, Roy Maimon, Steven F. Dowdy, Neal K. Devaraj, Zhuan Zhou, William C. Mobley, Don W. Cleveland & Xiang-Dong Fu.

Contributors

  • Xiang-Dong Fu

  • Lauren Richardson is the Founder and Principal of LR Bio LLC.

More From These Contributors

The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, this content may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein.

This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets) is available at https://a16z.com/investments/.

Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.

go to top